Recently, osimertinib was recommended as first-line treatment for patients with EGFR-mutant NSCLC according to the FLAURA trial that reported significantly better PFS and OS with osimertinib than with first-generation EGFR-TKIs (gefitinib or erlotinib) (6, 7). This evidence concerns the gene EGFR and non-small cell lung carcinoma.